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BACKGROUND The thoracic lymphadenectomy during an esophagectomy for esophageal cancer includes resection of
the thoracic duct (TD) compartment containing the TD lymph nodes (TDLNs). The role of TD compartment resection is
still a topic of debate since metastatic TDLNs have only been demonstrated in squamous cell carcinomas in Eastern
esophageal cancer patients. Therefore, the aim of this study was to assess the presence and metastatic involvement of
TDLNs in a Western population, in which adenocarcinoma is the predominant type of esophageal cancer.
METHODS From July 2017 to May 2020, all consecutive patients undergoing an open or robot-assisted transthoracic
esophagectomy with concurrent lymphadenectomy and resection of the TD compartment in the University Medical
Center Utrecht in Utrecht, the Netherlands, and the Citta della Salute e della Scienza University Hospital in Turin, Italy,
were included. The TD compartment was resected en bloc and was separated in the operation room by the operating
surgeon after which it was macroscopically and microscopically assessed for (metastatic) TDLNs by the pathologist.
RESULTS A total of 117 patients with an adenocarcinoma (73%) or squamous cell carcinoma (27%) of the esophagus
were included. In 61 (52%) patients, TDLNs were found, containing metastasis in 9 (15%) patients. No major compli-
cations related to TD compartment resection were observed.
CONCLUSIONS This study demonstrates the presence of metastatic TDLNs in adenocarcinomas of the esophagus.
This result provides a valid argument to routinely extend the thoracic lymphadenectomy with resection of the TD
compartment during an esophagectomy for esophageal cancer.
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CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).M ultimodality treatment, consisting of neoad-juvant chemo(radio)therapy and esophagec-tomy, is the standard of care for patients
with locally advanced esophageal cancer treated with
curative intent. The esophagectomy is performed with
an en bloc thoracic and abdominal lymphadenectomy.1-
3 The thoracic lymphadenectomy consists of a complete
resection of the lymph node (LN) stations surrounding
the esophagus and includes resection of the thoracicr publication Feb 22, 2021.
rrespondence to Prof. dr. van Hillegersberg, Department of Surge
, the Netherlands; email: R.vanHillegersberg@umcutrecht.nl.duct (TD) compartment.4 This compartment contains
the TD and its surrounding TDLNs. Resection of the TD
compartment is a feasible procedure that may increase
the (metastatic) LN yield.5-7
The anatomy of the esophageal lymphatics facilitates
spread to the TDLNs, as it consists of an extensive
network of vessels located in all layers of esophagus that
drain directly into the TD.8-10 The presence of metastatic
TDLNs has been demonstrated in 6% to 11% of patientsry, G04.228, University Medical Center Utrecht, Heidelberglaan 100, 3584
FIGURE 1 Thoracic duct compartment separat ion : (A ) complete resect ion specimen wi th en bloc resect ion of the thorac ic duct compar tment ,
(B ) enlarged view of the thorac ic duct compar tment wi th the d issect ion p lane, and (C) separated thorac ic duct compar tment . The b lack ar row
ind icates the Hem-o- lok mark ing the thorac ic duct ; the whi te dashed l ine ind icates the aor top leura l l igament , the dissect ion plane d iv id ing the
thorac ic duct compar tment , and the per iesophagea l t issue . (CAR, card ia of stomach; D, d is ta l ; ESO, esophagus; L , le f t ; P, p rox imal ; R , r ight . )
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Therefore, extension of the thoracic lymphadenectomy
with resection of the TD compartment has been advo-
cated and a standardized approach has been developed.5
However, resection of the TD compartment is not
routinely performed in all centers in the Western world,
as metastatic involvement of TDLNs has not been
demonstrated in adenocarcinomas, which is the most
common histological subtype of esophageal cancer in
the Western population.12 Additionally, TD resection is
associated with an increase in postoperative complica-
tions such as chyle leakage and recurrent nerve
injury.13,14 However, this has been contradicted in liter-
ature and a general consensus is lacking, resulting in
different surgical strategies across centers.15-17
Therefore, the aim of this study was to assess the
presence of TDLNs and the metastatic involvement ofthese nodes in patients with SCCs or adenocarcinomas
of the esophagus. To assess the safety of TD
compartment resection, associated complications were
reported.PATIENTS AND METHODS
STUDY POPULATION. Between July 2017 and May 2020,
all consecutive patients with a histologically proven
adenocarcinoma or SCC of the esophagus who under-
went a transthoracic esophagectomy with a 2-field or 3-
field lymphadenectomy and resection of the TD
compartment in the University Medical Center Utrecht
in Utrecht, the Netherlands, and the A.O.U. Citta della
Salute e della Scienza in Turin, Italy, were included.
Patient, tumor, and clinical characteristics were
extracted from a prospectively maintained database.
TABLE 1 Patient Demographics and Tumor
Characteristics
Characteristic n ¼ 117




BMI, kg/m2 25 ± 4
Histopathologya
Adenocarcinoma 85 (73)

























aDetermined in pretreatment biopsy; bBased on the 7th edition of the American
Joint Committee on Cancer Cancer Staging Manual. Values are mean ± SD or
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Institutional review board approval was obtained and
the need for informed consent was waived.
CLINICAL STAGING. The standard diagnostic workup for
clinical staging consisted of an endoscopy with biopsies,
an endoscopic ultrasound, and a contrast computed to-
mography scan of the neck, thorax, and abdomen. A 18F-
fluorodeoxyglucose positron emission tomography–
computed tomography (PET-CT) was routinely
performed in the Netherlands and in selected cases in
Italy. Staging was done according to the 7th edition of
the American Joint Committee on Cancer Cancer
Staging Manual.18
SURGICAL PROCEDURE. An open or robot-assisted
transthoracic esophagectomy was performed by
dedicated upper gastrointestinal surgeons (the
Netherlands: R.v.H., J.P.R.; Italy: R.R., P.S.). During thethoracic part of the procedure, mobilization of the
esophagus was combined with the thoracic
lymphadenectomy, which included the right and left
paratracheal (station 2R, L), tracheobronchial (station
4R, L), aortopulmonary window (station 5), subcarinal
(station 7), periesophageal (station 8M, L), and
pulmonary ligament (station 9) LNs and en bloc
resection of the TD compartment.18 As previously
described, the TD compartment is anatomically defined
by the aortoesophageal and aortopleural ligament
anteriorly, by the spine posteriorly, and by the azygos
vein and aorta laterally.5,10 The TD was ligated 5 cm
above the diaphragm which is the surgical caudal
border of the TD compartment. At this location most of
the abdominal tributaries have merged with the TD.19
The surgical cranial border of the TD compartment is
located in the left thoracic inlet. At this location, the
TD is transected with a bipolar vessel sealer. The
operating surgeon separated the TD compartment from
the resection specimen by following the dissection
plane provided by the aortoplural ligament, after
which it was sent to the Pathology Department
(Figure 1).10 If there was suspicion of tumor invasion in
the TD compartment, the compartment was marked
and separated by the pathologist to ensure a reliable
assessment of the circumferential resection margin.
PATHOLOGICAL ASSESSMENT OF THE TD
COMPARTMENT. A standard protocol was used for eval-
uation of the resection specimen. The entire TD
compartment was inspected macroscopically, and
visible LNs were separated and embedded in paraffin, as
was the remaining part of the TD. For the microscopic
assessment of TDLNs, 4-mm sections were made and
stained with hematoxylin and eosin. The number of
TDLNs, metastatic involvement, and response to neo-
adjuvant treatment were assessed. Tumor-positive LNs
were defined as LNs containing metastatic disease
regardless of the size of the metastasis. Pathological
assessment was done according to the College of
American Pathologists.
TD RESECTION–ASSOCIATED POSTOPERATIVE
COMPLICATIONS. Chyle leakage and recurrent nerve
injury were assessed during hospital admission and
registered in a weekly consensus meeting. Complica-
tions were defined according to the Esophagectomy
Complications Consensus Group (ECCG) and severity
was registered according to the Clavien-Dindo
classification.20,21
DATA ANALYSIS. Patient and tumor characteristics were
described as count and percentage, mean  SD, or me-
dian (range) where appropriate. Data analysis was per-
formed using SPSS version 26 (IBM Corporation,
Armonk, NY).
TABLE 2 Pathology Results

















No neoadjuvant treatment 23 (20)
LN yield 37 (10-96)




aNumber of positive nodes if LN metastasis was present. Values are n (%) or
median (range). LN, lymph node; TDLN, thoracic duct lymph node.
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STUDY POPULATION. A total of 117 patients were
included, with a mean age of 67  10 years, and 83 (71%)
were men. Most patients had a histologically proven
adenocarcinoma (73%) of the distal esophagus (78%). A
clinical T3 stage (78%) was most frequent with clinically
suspected LN metastasis in 82 (70%) patients. A majority
of patients (80%) received neoadjuvant treatment, con-
sisting of chemoradiotherapy in 70% of the cases. A
complete overview of patient and tumor characteristics
is presented in Table 1.
HISTOPATHOLOGICAL RESULTS. A pathological T3 stage
was observed in the majority of patients (38%). Among
patients who received neoadjuvant treatment, a patho-
logical complete response (Mandard 1) was observed in
25%. The median number of resected LNs was 37 (range,TABLE 3 Presence of (Metastatic) TDLNs
Variable n ¼ 117
TDLN present 61 (52)
Number of TDLNs 2 (1-11)
Patients with metastatic TDLNs 9 (8)
Number of metastatic TDLNs 1 (1-2)
Values are n (%) or median (range). TDLN, thoracic duct lymph node.10-96) with LN metastasis in 40% of the patients. In the
patients with LN metastasis, a median of 2 (range, 1-20)
tumor-positive LNs were found (Table 2).
THORACIC DUCT LNS. TDLNs were present in 61 (52%)
patients, with a median number of 2 (range, 1-11) nodes
per patient. Of these patients, 9 (15%) had metastatic
TDLNs, with a median of 1 (range, 1-2) metastatic node
(Table 3). In 1 patient, the metastatic TDLN was the only
tumor-positive LN in the resection specimen. Metastatic
TDLNs were observed in both SCCs (3%, n ¼ 1 of 31) and
adenocarcinomas (10%, n ¼ 8 of 85) with a pathologic T3
stage, all located at the distal esophagus. None of the
metastatic TDLNs were visible during diagnostic
imaging. A total of 8 of 9 patients with metastatic
TDLNs received neoadjuvant treatment. Regressive
changes in the TDLNs were observed in 2 of the
patients that received neoadjuvant treatment. A
complete overview of the patients with metastatic
TDLNs is provided in Table 4.
TD RESECTION–ASSOCIATED POSTOPERATIVE
COMPLICATIONS. An uncomplicated postoperative
course was observed in 30 (26%) patients. Chyle leakage
was observed in 5 (4%) patients and recurrent nerve
injury in 14 (12%) patients, of which 12 cases were left-
sided. Surgical treatment of chyle leakage was required
in 2 patients and was graded as type III according to
the ECCG classification. In these patients, video-
assisted thoracoscopic surgery was performed to locate
and repair the leak. In both cases, the leakage was of
the TD distal from the initial ligation and was stopped
through mass ligation of the area caudal to the leak.
All patients with recurrent nerve injury had transient
complaints that were conservatively treated and were
graded as type I according to the ECCG classification
(Table 5).20COMMENT
This study demonstrates the presence of TDLNs in 52%
of patients, of which 15% contained metastasis, even
after neoadjuvant therapy. Metastatic TDLNs were
observed in both adenocarcinomas and SCCs. Post-
operative complications associated with TD resection
such as chyle leakage and recurrent nerve injury were
observed in 4% and 12%, respectively, and were of
limited severity in most cases.
This report demonstrates the presence of metastatic
TDLNs in adenocarcinomas of the esophagus and sub-
stantiates previous research on the existence of meta-
static TDLNs in SCCs.6,7 The presence of metastatic
TDLNs in both adenocarcinomas and SCCs, even after
neoadjuvant treatment, provides a valid argument to
extend the thoracic lymphadenectomy with resection of
the TD compartment. Standard resection of the TD
TABLE 4 Characteristics of Metastatic Thoracic
Duct Lymph Nodes
Characteristic n ¼ 9
Histopathology
Adenocarcinoma 8 (89)


























No neoadjuvant treatment 1 (11)
aBased on the 7th edition of the American Joint Committee on Cancer
Cancer Staging Manual. Values are n (%).
TABLE 5 Postoperative Complications Associated
With Thoracic Duct Resection
Complicationa n (%)
Uncomplicated procedures 30 (26)
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compartment leads to an increase in LN yield, which is
associated with an improved prognosis.22 Additionally,
resection of metastatic TDLNs will increase the onco-
logic radicality of this procedure.
Assessment of the presence of (metastatic) TDLNs on
diagnostic imaging might aid in the decision to remove
the TD compartment. However, the assessment of LNs
on conventional imaging remains challenging even in
the case of LN metastasis. In 24% of the included pa-
tients with a clinical N0 stage, tumor-positive nodes
were found upon pathological assessment. This in-
dicates the inability of current diagnostic imaging tech-
niques to accurately identify nodal metastasis
preoperatively. Therefore, resection of the TD compart-
ment should not be based on imaging, but rather on the
considerable possibility of LN metastasis in this
compartment.
It should be noted that TDLNs were absent in 48% of
the included patients and that in these patients routine
resection other TD compartment does not contribute to
an increased (metastatic) LN yield. The absence ofTDLNs in some patients is in line with previous reports
in which TDLNs were found in 67% of the patients. The
varying presence of LNs in well-defined thoracic LN
stations such as stations 2, 4, 8, and 9 has been previ-
ously reported in cadaver studies.23 It might well be
hypothesized that these variations also apply to the
TDLNs.
The most common complications that have been
associated with resection of the TD compartment are
chyle leakage and recurrent nerve injury.13,14 To provide
insight in the safety of TD compartment resection, these
complications were assessed in the current report. Of
these complications, chyle leakage is associated with the
highest morbidity and mortality. Chyle leakage occurred
in 4%, which is comparable to the incidence observed in
previous reports assessing complications associated with
esophagectomy.20 The observed recurrent nerve injury
rate of 12% is significant, but within the range of 4% to
30% that has been reported in literature.14,20,24-27 With
that, all complaints were of transient nature and were
graded as type I according to the ECCG classification,
indicating that no therapy was needed.20 The incidence
of these complications suggests that resection of the TD
compartment can be performed safely. In addition, both
chyle leakage and recurrent nerve injury have a multi-
factorial etiology, and the increased risk of these com-
plications that is attributable to TD compartment
resection remains unclear. This particularly accounts for
recurrent nerve injury. Regarding the anatomy of the
recurrent nerve region, it is improbable that TD resection
causes recurrent nerve injury. The TD compartment and
the recurrent nerve region are 2 distinct compartments
that can be dissected independently.28 Therefore,
recurrent nerve injury is presumably caused by either
resection of the paratracheal and aortopulmonary win-
dow LNs (ie, stations 4 and 5) or the left cervical
dissection in case of a McKeown approach.29
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the routine resection of the TD compartment in the
participating centers, we were not able to directly
compare a TD-resected group and a TD-preserved group
in terms of perioperative, oncological outcomes as well
as in terms of survival. However, a recently published
report demonstrated that besides a statistically signifi-
cant longer operating time, there were no differences in
terms of blood loss and postoperative complications
between TD-resected and TD-preserved groups.15 Our
report provides convincing evidence of the presence of
metastatic TDLNs in both SCCs and adenocarcinomas of
the esophagus. Routine resection of these nodes might
have a considerable impact on the oncological
completeness of an esophagectomy for esophageal can-
cer. These oncological benefits and the comparable
perioperative results in the previous literature substan-
tiate the added value of extending the thoracic lym-
phadenectomy with resection of the TD compartment.
Nevertheless, our report does not demonstrate a survival
benefit related to the resection of the TD compartment,
which would be a more conclusive argument to
routinely resect the TDLNs. To demonstrate a survival
benefit, a randomized controlled trial with an interven-
tion arm (ie, resection of TD compartment) and a control
arm (ie, preservation of the TD compartment) would be
the preferred method. However, because this report
evidently demonstrates the presence of metastatic
TDLNs, it would be in conflict with the surgical onco-
logical principles to design a randomized controlled trialin which these metastatic LNs might not be resected (ie,
the control arm). Therefore, this report together with
previous literature regarding this subject might be the
highest level of evidence that can be provided.
The current report demonstrates that extending the
standard thoracic lymphadenectomy with resection of
the TD compartment is feasible in open as well as robot-
assisted minimally invasive esophageal surgery. Stan-
dardized steps for TD compartment resection have been
described, and the anatomical borders of the TD
compartment allow for a clear identification and metic-
ulous dissection.5 Therefore, adding the resection of TD
compartment to an existing procedure is relatively
straightforward. However, it should be taken into ac-
count that the alteration of an existing procedure might
be subject to a learning curve.
In conclusion, this study confirms the presence of
metastatic TDLNs in patients with esophageal SCC and
demonstrates the presence of metastatic TDLNs in pa-
tients with adenocarcinoma of the esophagus. These
results provide a valid argument to routinely resect the
TD compartment. Related postoperative complication
rates were relatively mild and, in our opinion, accept-
able with regard to the increased oncological
completeness that is achieved with resection of the
TDLNs. Therefore, this report should act as an incentive
to consider the extension of the thoracic lymphade-
nectomy with resection of the TD compartment in pa-
tients undergoing an esophagectomy for esophageal
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